# Ortoma

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ortoma).

## Overview

Ortoma is a Swedish medical technology company focused on AI-based systems for orthopedic surgery. Its core platform, OTS™, is designed for planning, navigation, and follow-up of implant and prosthesis procedures and is built to work across different implant suppliers and healthcare markets.

## Products & services

• OTS™ Hip surgical planning and navigation system
• OTS™ platform and related software modules
• Hardware systems for operating-room use
• Software licenses for clinical use
• Consumables used during each procedure

- **Hardware systems** (45%) — Operating-room hardware sold as part of the OTS™ solution.
- **Software licenses** (30%) — Recurring licenses for the OTS™ planning and navigation platform.
- **Consumables** (15%) — Single-use items consumed during orthopedic procedures.
- **Service and support** (10%) — Implementation, support, and related commercial services around the platform.

- OTS™ Hip surgical planning and navigation system
- OTS™ platform and related software modules
- Hardware systems for operating-room use
- Software licenses for clinical use
- Consumables used during each procedure

## Customers

Ortoma sells primarily through distributors and strategic partners, so its direct commercial counterparties are often large healthcare technology or implant-related organizations. The end users are hospitals and clinics performing orthopedic implant and prosthesis procedures, which buy the system to improve surgical workflow, precision, and follow-up.

- **Hospitals** (primary) — Buy OTS™ systems and licenses for orthopedic operating rooms to improve planning and navigation.
- **Clinics and surgical centers** (secondary) — Use the platform for hip and other orthopedic procedures where workflow and precision matter.
- **Distributors and strategic partners** (primary) — Purchase and resell the solution, helping Ortoma reach markets and end users.
- **Implant and medical device ecosystem partners** (secondary) — Adopt compatible digital tools that can integrate with their implant offerings.

- Hospitals that perform orthopedic implant and prosthesis surgery
- Clinics seeking planning and navigation tools for hip procedures
- Distributors and strategic partners that commercialize the system
- Healthcare systems that value workflow efficiency and surgical precision
- Implant ecosystem partners that benefit from compatible digital tools

## Geography

Ortoma develops its products for a global market and adapts commercialization to local reimbursement systems, regulation, and market structure. The company has highlighted planned expansion across major healthcare markets, with commercialization shaped by distributor partnerships rather than a single-country operating footprint.

- Global product design with market-specific commercialization
- Sales depend on local reimbursement and regulatory frameworks
- Distribution partnerships are used to enter new countries
- Market rollout can differ by healthcare system and adoption speed
- Future revenue mix is expected to become more recurring across markets

## Strategy

Ortoma's strategy is to commercialize OTS™ through strategic partnerships and a distributor-led model that can scale internationally. It is also building a more recurring revenue base over time by combining hardware sales with software licenses and consumables, while broadening the platform beyond the initial hip application.

- **Commercialize OTS™ through distributor partnerships** (short-term) — Partners provide market access and reduce the need for a large direct sales footprint.
- **Grow recurring revenue mix** (medium-term) — Software licenses and consumables can create a more predictable revenue profile than one-time hardware sales.
- **Broaden the platform beyond OTS™ Hip** (long-term) — Additional indications can expand the addressable market and leverage the same technical platform.

- Use strategic partnerships to reach global orthopedic markets
- Expand from one application into additional clinical use cases
- Increase recurring revenue from licenses and consumables
- Adapt commercialization to local reimbursement and regulation
- Build installed base to support repeat sales over time

## Risks

Ortoma's business depends on successful commercialization, clinical adoption, and continued access to qualified personnel and capital. As a medical technology company selling through regulated healthcare channels, it also faces product acceptance, data security, legal, currency, and competition risks that can affect both growth and reported results.

- **Dependence on key personnel** [high] — The company relies on a small number of people with specialized knowledge and creativity.
- **Commercial adoption risk** [high] — Demand for current and future products may be lower or slower to develop than expected.
- **Market acceptance of new products** [medium] — New launches may be outcompeted or fail to gain traction with hospitals and clinicians.
- **Data privacy and cybersecurity** [high] — The business may process sensitive personal and clinical data and could face breaches or compliance failures.
- **Foreign exchange exposure** [medium] — Sales are made globally, with significant USD exposure while many costs are in SEK and EUR.
- **Funding and going-concern dependence** [high] — The company has historically depended on external capital until operations become self-funding.

- Commercial adoption may be slower than expected
- New products may not gain market acceptance
- Business depends on key personnel and specialized know-how
- Data privacy and cybersecurity failures could damage trust
- Global sales create foreign exchange exposure

## Accounting

Ortoma's reported revenue profile is affected by the mix between hardware, software licenses, and consumables, which can shift the timing of recognition between upfront and recurring sales. Investors should also watch capitalization of development costs and patents, as well as any impairment testing of intangible assets if commercialization or adoption is slower than expected.

- **Revenue recognition across hardware, licenses, and consumables** — Mix shifts can change the share of recurring revenue and reported growth
- **Capitalized development expenditures** — Amortization and impairment can materially affect earnings and equity
- **Patent and intangible asset impairment** — Could create non-cash write-downs
- **Foreign currency effects** — Can affect revenue, expenses, and net result period to period

- Revenue timing depends on hardware versus recurring license sales
- Consumables and software can increase recurring revenue recognition
- Capitalized development costs affect asset values and future amortization
- Patent and intangible asset impairment is a key judgment area
- Foreign currency translation and transaction effects can move reported results

---

*Last updated: 2026-08-11T04:04:55.152971+00:00*